NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer, candidates to receive maintenance therapy with trastuzumab plus pertuzumab (HP) after first line treatment for metastatic disease with a taxane or vinorelbine plus HP.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.